These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 31486169)

  • 1. The effect of baseline antipsychotic status on the 12-month outcome in initially stabilized patients with schizophrenia.
    Fountoulakis KN; Panagiotidis P; Nimatoudis I
    Hum Psychopharmacol; 2019 Sep; 34(5):e2712. PubMed ID: 31486169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 12-Month stability of neurological soft signs in stabilized patients with schizophrenia.
    Fountoulakis KN; Panagiotidis P; Kimiskidis V; Nimatoudis I
    Nord J Psychiatry; 2019 Oct; 73(7):451-461. PubMed ID: 31393751
    [No Abstract]   [Full Text] [Related]  

  • 3. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study.
    Novick D; Haro JM; Suarez D; Vieta E; Naber D
    Schizophr Res; 2009 Mar; 108(1-3):223-30. PubMed ID: 19070991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher than recommended dosages of antipsychotics in male patients with schizophrenia are associated with increased depression but no major neurocognitive side effects: Results of a cross-sectional pilot naturalistic study.
    Fountoulakis KN; Gonda X; Siamouli M; Moutou K; Nitsa Z; Leonard BE; Kasper S
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Apr; 75():113-119. PubMed ID: 28137432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year Outcome of First vs. Later Episode Schizophrenia: A Real-world Naturalistic Study.
    Fountoulakis KN; Panagiotidis P; Theofilidis AT; Nimatoudis I
    Clin Psychopharmacol Neurosci; 2020 Aug; 18(3):434-444. PubMed ID: 32702222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Antipsychotic Drugs for 24-Month Maintenance Treatment in First-Episode Schizophrenia: Evidence From a Community-Based "Real-World" Study.
    Zhang C; Chen MJ; Wu GJ; Wang ZW; Rao SZ; Zhang Y; Yi ZH; Yang WM; Gao KM; Song LS
    J Clin Psychiatry; 2016 Nov; 77(11):e1460-e1466. PubMed ID: 28076667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: A single-blinded, 52-week, randomized controlled study.
    Zhou Y; Li G; Li D; Cui H; Ning Y
    J Psychopharmacol; 2018 May; 32(5):524-532. PubMed ID: 29493377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial.
    Schoemaker JH; Jansen WT; Schipper J; Szegedi A
    J Clin Psychopharmacol; 2014 Apr; 34(2):190-8. PubMed ID: 24525661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Bae KY; Yang SJ; Yoon JS
    Clin Neuropharmacol; 2010 May; 33(3):121-5. PubMed ID: 20502130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
    Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
    Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication.
    Widschwendter CG; Kemmler G; Rettenbacher MA; Yalcin-Siedentopf N; Hofer A
    BMC Psychiatry; 2018 Jun; 18(1):212. PubMed ID: 29954366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study.
    Harrow M; Jobe TH; Faull RN
    Psychol Med; 2012 Oct; 42(10):2145-55. PubMed ID: 22340278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Gaebel W; Riesbeck M; Wölwer W; Klimke A; Eickhoff M; von Wilmsdorff M; Heuser I; Maier W; Klosterkötter J; Falkai P; Schlösser R; Schmitt A; Riedel M; Klingberg S; Köpcke W; Ohmann C; Möller HJ
    Schizophr Res; 2014 Feb; 152(2-3):478-86. PubMed ID: 23643327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insight and recovery in schizophrenic patients.
    Cannavò D; Minutolo G; Battaglia E; Aguglia E
    Int J Psychiatry Clin Pract; 2016; 20(2):83-90. PubMed ID: 26902557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.